FILE PHOTO: The logo of Lupin, India's No. 2 drugmaker, is seen on the facade of its pharmaceutical plant in Verna FILE PHOTO: The logo of Lupin, India's No. 2 drugmaker, is seen on the facade of its ...
USD 90 million, which includes a Prepaid Option Payment of USD 75 million, and (2) a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September ...
The settlement resolves Lupin's pending litigation with Astellas and enables the company to continue marketing Mirabegron in the United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results